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Abstract
Background: Physical exercise, cognitive training, and vitamin D are low cost interventions that have the potential to
enhance cognitive function and mobility in older adults, especially in pre-dementia states such as Mild Cognitive
Impairment (MCI). Aerobic and progressive resistance exercises have benefits to cognitive performance, though
evidence is somewhat inconsistent. We postulate that combined aerobic exercise (AE) and progressive resistance
training (RT) (combined exercise) will have a better effect on cognition than a balance and toning control (BAT)
intervention in older adults with MCI. We also expect that adding cognitive training and vitamin D supplementation to
the combined exercise, as a multimodal intervention, will have synergistic efficacy.
Methods: The SYNERGIC trial (SYNchronizing Exercises, Remedies in GaIt and Cognition) is a multi-site, double-blinded,
five-arm, controlled trial that assesses the potential synergic effect of combined AE and RT on cognition and mobility,
with and without cognitive training and vitamin D supplementation in older adults with MCI. Two-hundred participants
with MCI aged 60 to 85 years old will be randomized to one of five arms, four of which include combined exercise plus
combinations of dual-task cognitive training (real vs. sham) and vitamin D supplementation (3 × 10,000 IU/wk. vs. placebo)
in a quasi-factorial design, and one arm which receives all control interventions. The primary outcome measure is the
ADAS-Cog (13 and plus modalities) measured at baseline and at 6 months of follow-up. Secondary outcomes include
neuroimaging, neuro-cognitive performance, gait and mobility performance, and serum biomarkers of inflammation
(C reactive protein and interleukin 6), neuroplasticity (brain-derived neurotropic factor), endothelial markers (vascular
endothelial growth factor 1), and vitamin D serum levels.
Discussion: The SYNERGIC Trial will establish the efficacy and feasibility of a multimodal intervention to improve
cognitive performance and mobility outcomes in MCI. These interventions may contribute to new approaches to
stabilize and reverse cognitive-mobility decline in older individuals with MCI.
(Continued on next page)
* Correspondence: mmontero@uwo.ca
1Department of Medicine, Division of Geriatric Medicine, Schulich School of
Medicine & Dentistry, University of Western Ontario, London, Canada
2Department of Epidemiology and Biostatistics, Schulich School of Medicine
& Dentistry, University of Western Ontario, London, Canada
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Montero-Odasso et al. BMC Geriatrics  (2018) 18:93 
https://doi.org/10.1186/s12877-018-0782-7
(Continued from previous page)
Trial Registration: Identifier: NCT02808676. https://www.clinicaltrials.gov/ct2/show/NCT02808676.
Keywords: MCI, Exercise, Cognitive training, Vitamin D, Cognition, Gait, Dementia
Background
Over 46 million people lived with dementia worldwide
in 2015, with 1 new case every 4.1 s [1]. The cost associ-
ated with these dementia cases is over $800 billion US
[1]. There is no cure for dementia. Recently, there has
been an important shift in interventional studies on
dementia to targeting early stages or pre-dementia
states. Mild cognitive impairment (MCI) is thought to
be an intermediate state between normal cognition of
aging and very early dementia and, as a pre-dementia
state, is commonly regarded as the optimal stage to
intervene with preventive strategies and early treatments
[2, 3]. Promising interventions for people with MCI
include physical exercise, cognitive training, and vitamin
D supplementation.
Physical exercise, specifically aerobic exercise (AE) and
progressive resistance training (RT), have been demon-
strated to improve cognitive outcomes, along with
improved physical capacity and mobility in older adults
[4, 5]. Both, AE [6] and RT [7] trials have reported posi-
tive results in improving cognitive performance, with
consistent findings also observed after AE interventions
lasting more than 3 months [4, 8]. RT has been studied
less extensively than aerobic training in older adults,
particularly in Mild Cognitive Impairment (MCI).
Similarly, cognitive training (e.g., computer based cogni-
tive process training) may improve cognition, mobility,
and postural control in older adults. Recent systematic
reviews have shown cognitive benefits of computer-based
cognitive training [9, 10]. Notably, a dual-task cognitive
training regimen designed by our group has demonstrated
that this type of training can also improve balance in
healthy older adults [11]. Recent research suggests that
improvements in brain plasticity occur after cognitive
training [12, 13].
Vitamin D deficiency has been associated with cognitive
dysfunction, dementia and mobility decline in older adults
[4, 14–16]. Vitamin D is a neurosteroid hormone that
exhibits neuroprotective attributes through antioxidative
mechanisms, neuronal calcium regulation, immunomodu-
lation, enhanced nerve conduction, and detoxification
mechanisms [14, 17–20]. Compelling evidence from animal
models and epidemiological studies supports a potential
beneficial role for vitamin D on cognitive function [18, 21].
Robustly designed trials with longitudinal follow-up
have been recommended to investigate the comparative
benefits of isolated and multi-domain interventions in
MCI to improve cognition and function [22]. To date,
the effect of combined AE and RT in MCI is unknown.
Moreover, the added value of adding cognitive training
and vitamin D supplementation to physical exercise
for improving global cognition, executive function,
and memory in MCI has not been assessed. [22] The
SYNERGIC TRIAL (SYNchronizing Exercises, Remed-
ies in GaIt and Cognition) is designed to evaluate the
effect of the combined exercise (AE and RT), alone or
in combination with cognitive training and vitamin D
supplementation, in older adults with MCI. This trial is
being conducted by the Motor Exercise and Cognition
Team (MEC Team 12) of the Canadian Consortium on
Neurodegeneration in Aging (CCNA), part of the Canada
Dementia Strategy.
Hypotheses
1. Twenty weeks of supervised combined exercise (AE
and RT) will significantly improve cognitive
function in older adults with MCI, as assessed by
primary outcome Alzheimer’s Disease Assessment
Scale-Cognitive (ADAS-Cog 13 and plus modalities)
and secondary outcomes, compared to a balance and
toning (BAT) control.
2. Adding cognitive training to combined exercise will
significantly improve primary and secondary outcomes
compared to combined exercise without cognitive
training.
3. Adding vitamin D supplementation to combined
exercise will significantly improve primary and
secondary outcomes compared to combined
exercise without vitamin D supplementation.
4. The multi-domain intervention (combined exercise
+ cognitive training + vitamin D supplementation)
will significantly improve primary and secondary
outcomes compared to the control intervention.
Methods/Design
Design
The SYNERGIC TRIAL (SYNchronizing Exercises,
Remedies in GaIt and Cognition) is a randomized,
phase II, five-arm, double-blind controlled study evalu-
ating the effect of combined exercise with and without
cognitive training and vitamin D supplementation on
cognitive function. A total of 200 participants with
MCI, aged 60 and older will be enrolled and random-
ized into one of five arms:
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Arm 1: combined AE and RT exercise + cognitive
training + vitamin D.
Arm 2: combined AE and RT exercise + cognitive
training + placebo D.
Arm 3: combined AE and RT exercise + control cogni-
tive training + vitamin D.
Arm 4: combined AE and RT exercise + control cogni-
tive training+ placebo D;
Arm 5: BAT exercise + control cognitive training +
placebo D.
Note: The active interventions are in bold. Arm 5
includes only control interventions.
Figure 1 illustrates the trial design and Fig. 2 summa-
rizes the timeline of the trial consisting of an approxi-
mate 12–18 months enrolment period, and 12 months
of follow-up. The trial adheres to the Consolidated
Standards of Reporting Trials guidelines for the conduct
and reporting of clinical trials, as extended to non-
pharmacologic interventions [23].
Setting
Interventions will be done across five sites: London (lead
and sponsor site), Waterloo-University of Waterloo,
Waterloo-Wilfrid Laurier University, Montreal, and
Vancouver. Participants will be recruited primarily




The target recruitment is 200 older adults aged 60 to
85 years old with MCI who meet inclusion and exclusion
criteria as outlined here (London target recruitment: 40
participants, Waterloo-University of Waterloo target
recruitment: 20, Waterloo-Wilfred Laurier University
target recruitment: 20, Montreal target recruitment: 50,
and Vancouver-University of British Columbia target
recruitment: 70). Although age, sex, and education will
be included as covariates in the analytical models,
recruitment will not be stratified.
Inclusion criteria
Participants must meet each of the following criteria for
enrolment into the study:
1. Age 60 to 85 years old.
2. Self-reported levels of proficiency in English, or
French (at Montreal site only), for speaking and
understanding spoken language.
Fig. 1 Consortium flowchart for the SYNERGIC Trial
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3. Able to comply with scheduled visits, treatment
plan, and other trial procedures.
4. Able to ambulate at least 10 m independently.
5. Having MCI defined following Albert et al. [2]
criteria:
a- Subjective cognitive complains,
b- Objective cognitive impairment in one of the
following four cognitive domains: memory,
executive function, attention, and language,
operationalized using one or more of the
following: MoCA Test (Montreal Cognitive
Assessment) with scores ranging from 13 to 24/
30, Logical Memory below Alzheimer’s Disease
Neuroimaging Initiative (ADNI) cut-offs (< 9 for
16+ years of education; < 5 for 8–15 years of
education; < 3 for 0–7 years of education),
Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) word list recall < 6.
c- Preserved activities of daily living operationalized as
a Score > 14/23 on the Lawton-Brody Instrumental
Activities Of Daily Living (IADL) [24] scale and
confirmed by clinician’s interviews.
d- Absence of dementia using criteria from the
Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition [25] and/or Global
Clinical Dementia Rating (CDR) ≤ 0.5 [26].
6. Having normal or corrected to normal vision in
at least one eye so that they can identify symbols
and stimuli presented on a computer screen in
front of them.
7. Must be in sufficient health to participate in the
study’s exercise training program as determined
using the Physical Activity Readiness
Questionnaire-Plus (PARQ+) screening tool,
coupled with evaluation by a certified exercise
physiologist and/or a physician for clearance to
participate in combined exercise training program.
Fig. 2 Schematic Timeline of the SYNERGIC Trial. a Recruitment of participants will be an on-going process with individuals being assigned to groups as
they are enrolled. Recruitment is expected to be finished between 12 to 18 months. b Baseline assessments (T0) will be completed within one-week of
participant starting the specific intervention/placebo. Participants will return to the clinic six months (c) after starting the specific intervention/placebo to
complete the post intervention assessment (T6). After six months participants will return to the clinic again (T12) at which time their final assessment will
be completed (d). 9 months after their first baseline assessment (T0) i.e. 3 months post-intervention, there will be a follow-up phone call
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Exclusion criteria
Participants who exhibit any of the following conditions
are to be excluded from the study:
1. Serious underlying disease which, in the opinion of
the investigator, may preclude engagement in
interventions or may interfere with the participant’s
ability to participate fully in the study.
2. Participant with uncontrolled major depression,
schizophrenia, severe anxiety or drug abuse.
3. Current parkinsonism or any neurological disorder
with residual motor deficits (e.g. stroke with motor
deficit), active musculoskeletal disorders (e.g. severe
osteoarthritis of lower limbs) or history of knee/hip
replacement affecting gait performance at clinical
evaluation.
4. Intention to enroll in other clinical trials during the
same time period.
5. Active participation in an exercise program
involving AE or RT regimen 2 or more times per
week in previous 6 months.
6. Taking vitamin D, cognitive enhancers,
neuroleptics, or anticholinergics.
7. Known hypercalcemia and/or disorder that is cause
of hypercalcemia (e.g. hyperparathyroidism/ Paget’s
disease/ Sarcoidosis).




Sample size calculation is based on changes in our
primary outcome: global cognitive function measured
using the Alzheimer Disease Assessment Scale Cognitive
13 and the plus modality (ADAS-Cog 13 and plus).
Changes in the ADAS-Cog test has been used as
primary outcome in pharmacological clinical trials in
dementia [27] and in 2 previous studies testing the effect
of exercises on cognition in MCI participants [28, 29]. A
total of 200 participants, with 160 in the combined
exercise (pooled from the first 4 arms in one group)
and 40 participant in the BAT control group, would
have 80% power to detect an effect size (mean differ-
ence divided by the standard deviation) of 0.5 at
2-sided, 5% significance level. In addition, two-group
comparisons with 80 participants per group would
have 88% power to detect an effect size of 0.5 at the
5% significance level. The effect size of 0.5 was
selected based on previous studies showing an effect
size of exercise on ADAS-Cog ranging from 0.6 to 0.3
in MCI populations. [28–30]. The sample size estima-
tions may be regarded as conservative, as the final
data will be analyzed using analysis of covariance
(ANCOVA) to adjust for baseline ADAS-Cog scores
and other important patient characteristics.
Measures
Test performed in the screening session, and during
three visits (baseline, 6 months, and 12 months) are
itemised in Table 1. Information concerning demograph-
ics, chronic diseases, comorbidities, chronic medications,
history of previous falls, fear of falling, and balance con-
fidence will be recorded using valid questionnaires at
baseline. Additional descriptors to be tested include the
activities of daily living using the Alzheimer Disease
Cooperative Study Activities of Daily Living inventory
(ADCS-ADL), Lawton-Brody IADL, the Short Form qual-
ity of life questionnaire (SF-36), the Generalized Anxiety
Disorder 7 (GAD 7), Geriatric Depression Scale (GDS-30),
CDR, the physical activity scale for the elderly (PASE), and
the Mini Mental State Examination (MMSE).
Primary outcome
Changes in cognitive function will be assessed using the
ADAS-Cog in two modalities, the 13 items modality
(ADAS-Cog 13) and the plus modality (ADAS-Cog plus,
Table 1) [25]. Improvement in either modality is consid-
ered evidence of efficacy. The ADAS-Cog 13 is a scale that
consists of 13 brief cognitive tests assessing memory,
language, attention, concentration and praxis. Scores
range from 0 to 84, with higher scores indicating higher
severity of cognitive impairment [25]. The ADAS-Cog has
been used a primary outcome measure in numerous trials
with MCI and Alzheimer’s Disease (AD) [28, 29]. The
ADAS-Cog plus has marked advantages over the ADAS-
Cog 13 as an outcome measure in MCI populations since
it incorporates items concerning executive function [25].
The following tests are adding to the ADAS-Cog 13 to
comprise the plus modality: Trail-Making Test (TMT) A
& B, the WAIS-R Digit Symbol Substitution Test (DSST),
the Digit Span forward & backward, and Category
Fluency. In brief, the TMT (A & B) is a two part test,
which assesses attention, speed, and mental flexibility and
has been widely used clinically for assessing deficits in
attention and executive functioning [31]. Trails A, where
participants connect numbers in ascending order is trun-
cated at 3 min and Trails B, where participants connect
numbers and letters in ascending and alternating order is
truncated at 5 min. Psychomotor speed is assessed with
the DSST [32], which evaluates the speed with which
participants copy arbitrary symbols associated with corre-
sponding digits, by referring to a number-symbol key at
the top of the page. The Digit Span test is an auditory
attention task, where participants are asked to recall a
series of numbers forward and backward. For category
fluency, a measure of speed and flexibility of verbal
thought, participants are asked to name as many items as
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possible in a specified category (vegetables & animals);
unique responses during the first minute in each category
are counted.
We expect that our interventions, over 20 weeks, will
show improvement and/or less decline in cognition as
measured by the ADAS-Cog (13 and plus modalities) at
month 6 and at month 12. Significant changes in either
time points will be considered preliminary evidence of
efficacy. Additionally, reducing the proportion of partici-
pants, expressed as percentages per allocated group, with
abnormal ADAS-Cog scores (dichotomous variable,
cut-off score to be determined with ADAS-Cog litera-
ture) after intervention will be considered evidence of
efficacy. Furthermore, we expect a significant statistical
improvement in the transformed score of ADAS-Cog
plus using an algorithm validated by Crane et al. [33].
Secondary outcomes
Secondary outcomes include neuropsychological assess-
ments, gait and mobility outcomes (including incidence
of fall), neuroimaging, and blood biomarkers.
Cognitive outcomes
Secondary cognitive outcomes will include MoCA test
for global cognition, the recall list from the ADAS-Cog
to evaluate verbal semantic memory, TMT A and B,
DSST, Digit Span Test (Forward and Backwards), Boston
Naming Test, Verbal fluency (animals and vegetables),











Written Informed Consent X
Demographic Information X
Mini Mental State Examination (MMSE) X
Physical Activity Readiness Questionnaire Plus (PARQ +) X
Logical Memory 1 & 2 X
CERAD Word List Recall X
PASE Questionnaire X
Montreal Cognitive Assessment (MoCA) X X X
Generalized Anxiety Disorder 7 (GAD-7) X X X
Geriatric Depression Scale (GDS-30) X X X
Clinical Dementia Rating (CDR) X X X
Activities of Daily Living (ADCS-ADL and IADL) X X X
Clinical Medical Questionnaire X X X
Dual Task Control Assessment X X X
ADAS-Cog 13 (+ tests a) X X X
Trail Making Test A & B a X X X
Digit Symbol Test a X X X
Digit Span Forward and Backward WAIS-III a X X X
Boston Naming Test a X X X
Verbal Fluency Test a X X X
Colour Word Interference Test X X X
Quality of Life Questionnaire (SF-36) X X X
Short Physical Performance Battery (SPPB) X X X
Gait Assessment using Gait Mat and accelerometers
(when available)
X X X
Six Minute Walk Test (6MWT) b X X X
Neuroimaging (MRI) X X
Blood Draw X X
Falls Calendar c X X X X
a Testing included in the ADAS-Cog plus
b This test may be completed at the gym facility on the first day of intervention
c Calendar will be given to participant to complete and will be submitted to Research Staff at exercise training
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and Colour Word Interference Test (Table 1). We expect
improvement in participants of the active intervention in
these cognitive tests, with the larger improvement in the
multimodal intervention.
Gait outcomes
Gait velocity and variability under single and dual-tasking
Gait velocity will be assessed as the time taken to walk
6 m using an electronic walkway system (ProtoKinetic®
and/or GAITRite® Systems, Inc.). Gait variability of
spatial and temporal gait variables (stride time, stride
length, double support time and step width) will be cal-
culated using the coefficient of variation (CV = (standard
deviation / mean) × 100). The CV is a standardized
measure of variability allowing comparison of gait vari-
ables measured in different units, having different means
and range of values. Gait walks will be performed 3
times under single-task conditions, and one time under
each of the three dual-task conditions (described below),
and one time as fast gait. Dual-tasking assessments will
permit calculation of dual-task cost for all gait variables
of interest [34, 35]. Specifically, we expect participants in
the combined exercise intervention to increase their gait
velocity, decrease their gait variability and reduce their
dual-task cost for the gait variables of interest.
Gait performance will be recorded using electronic
walkway systems which automatically determine spatio-
temporal gait parameters from imbedded sensors acti-
vated by foot pressure [36]. The gait mat will be located
in a well-lit room with start and end points marked on
the floor 1 m from either end of the mat. Participants
will perform three main tasks: 1) preferred walking
speed, 2) dual-task walking (counting backwards by 1’s,
subtracting 7’s, and naming animals out loud while walk-
ing) and 3) fast walking. In all walks, participants will
start 1 m before the beginning of the 6-m walkway and
continue to travel 1 m past the end of the walkway. This
procedure is in place to ensure steady-state walking
and to minimize any effects of acceleration and de-
acceleration during the course of the walk [37, 38].
The dual-task conditions selected are based on previ-
ous research which demonstrated that counting back-
wards requires both working memory and attention
[39] and naming animals is related to verbal fluency,
which relies on semantic memory [39, 40]. The evalu-
ator will record any counting errors during walking so
that it can be compared with the same mental tasks
while seated. The seated assessments will be timed at
10 s and will be performed in the beginning of all cog-
nitive assessments (before ADAS-Cog) to prevent
practice effects in dual-task gait performance. Reliabil-
ity has been previously established for this protocol in
people with MCI [41] and an instructive video can be
found at the “www.gaitandbrain.com/resources” as the
“Guidelines for Gait Assessments in CCNA”.
Falls
A fall is defined as ‘unintentionally coming to rest on
the ground, floor, or other lower level and not due to a
seizure, syncope, or an acute stroke’ [42]. Events caused
by overwhelming environmental hazards (e.g., being
struck by a moving object) are not considered a fall.
Recurrent falls are defined as ‘two or more events in a
12-month period’. Falls will be recorded throughout the
12-month trial, participants will be provided with a falls
calendars, on which they will record any falls that have
occurred, and they will be asked to bring them monthly
to the training sessions to review with a research staff
member. After the completion of the intervention, par-
ticipants will be contacted at month 9 and 12 to report
incidental falls. We expect participants in the combined
intervention to reduce the number of falls compared to
the sham intervention.
Mobility assessments
To further evaluate mobility, participants will be per-
forming the Short Physical Performance Battery (SPPB),
and the 6 min walk test (6MWT). We expect partici-
pants in the active intervention to present the larger
improvements.
Neuroimaging
Brain Magnetic Resonance Imaging (MRI) will be per-
formed at baseline and 6-month visit. The imaging protocol
will follow the Canadian Dementia Imaging Protocol devel-
oped for CCNA and available at http://www.cdip-pcid.ca.
Pre-post regional patterns of brain plasticity will be
assessed using structural (high-resolution 3D T1-weighted
images = 7 min) in order to get voxel-based volumetric and
cortical thickness measures, as well as diffusion tensor
imaging (DTI, 30 directions, with AP/PA correction scan =
7 min) to calculate fractional anisotropy and diffusivity in
white matter tracts as well as derive tract-based statistics.
Cerebrovascular integrity and pathology will be assessed
using the following contrasts: PD/T2 = 5 min; FLAIR =
7 min, and T2* = 5 min). Functional magnetic resonance
imaging at rest (rsfMRI plus field map = 12 min) will also
be acquired to measure change in data-driven functional
networks. Scanning time will take 1.3 h. We expect that all
active interventions will improve brain morphology (struc-
tural MRI), chemistry (spectroscopy MRI), and function
(resting state MRI) compared with control interventions
as defined by: increased hippocampal volume (mm3) by
MRI scanning; positive localized Voxel-Based Morphom-
etry (VBM) brain changes (z-score relative change); de-
creased total volume of White Matter Hyper-intensities
(WMHs) (mm3); and lead to beneficial hippocampal and
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anterior and posterior cingulate MRS metabolite changes
(% increase in N-acetylaspartate, and increase in phospho-
creatine metabolites) and resting state MRI prefrontal
activation.
Biological markers
A blood draw will take place at baseline and 6-month visit
in fasting conditions. Serum biomarkers of inflammation
(C reactive protein, and interleukin 6), neuroplasticity
(brain-derived neurotropic factor), endothelial health (vas-
cular endothelial growth factor 1), and vitamin D serum
levels will be measured before and after intervention.
Samples will be collected, processed and stored securely at
the respective site in a − 80 C freezer used for research
purposes. We expect that active interventions will
preferentially decrease inflammatory markers, increase
brain-derived neurotrophic factor (BDNF) levels [29],
and decrease vascular endothelial growth factor
(VEGF-1) compared to either cognitive or control
conditions.
Study procedures
The screening visit (visit 1) will determine participant’s
eligibility. There will be three assessment sessions: base-
line, post-intervention at 6 months, and 12-month
follow-up (Fig. 1). The baseline assessment will occur
prior to randomization. Outcomes will be assessed by
trained assessors blinded to group allocation. The mea-
sures at each assessment are described in Table 1 and
timelines are shown in Fig. 2.
Randomization
Upon completion of the screening and baseline assess-
ments, participants will be randomized and allocated to
one of the 5 study arm. The randomization sequence of
the participants will be generated centrally by the research
pharmacist of the sponsor site using a central, web-based
randomization service (www.randomizer.org) and will be
specific for each site. The research pharmacy will assign
the investigational product (vitamin D/matching placebo,
as “kits”) in compliance with the randomization list(s) and
allocate a sequential randomization number to each
participant. A block randomization by 5 will be applied to
ensure an appropriate balance of the characteristics of
participants between each arm. Permuted blocks will be
employed to ensure balance over time. After the baseline
assessment, research personnel not involved in measure-
ment or intervention will access the randomization list(s)
to determine the arm allocation and institute the corre-
sponding study interventions.
Blinding
In order to minimize a source of bias, this is a double-
blinded study. Research personnel performing the outcome
assessments at 6 and 12 month follow-ups will be blinded
to group allocation. Participants will be blinded to the
“active” intervention and study hypotheses. If it was medic-
ally necessary to un-blind a participant, the central research
pharmacy will be contacted by the principal investigator to
obtain the code.
Study interventions
All participants will participate in three (3) group-
training sessions per week for 20 weeks, under the
supervision of trainers. Each session will last approxi-
mately 90 min and will be comprised of 30 min cogni-
tive training or the cognitive training control followed
by approximately 60 min of combined AE and RT or
BAT control exercise. All participants will receive a
monthly supply of either a vitamin D supplement (tablet
10,000 IU) or a placebo to be taken three times per
week. All arms will have an equal volume and frequency
of contact with trainers over the 12 months of the study.
Interventions will be delivered in small groups of up to
eight individuals. Each training group will have 1–2
trainers present each session to ensure a ratio of one
trainer per four participants. To avoid potential imbal-
ances in exposure time, control conditions for exercise
and cognitive training will have the same duration as the
active interventions.
Combined AE and RT exercise
The combined exercise intervention will be held in appro-
priate fitness facilities and take place between Monday
and Friday, ensuring that it is not on three consecutive
days. Staff trained and certified in exercise training will
supervise all sessions. Difficulty of aerobic and resistance
exercise will be tailored to their individual functioning
level, with constant monitoring by the trainers.
Participants will start with a 10 min warm up, which
includes: marching in place with arm swings, bum kicks,
dynamic hamstring stretching, hula hoop circles, shoulder
circles, arm reaches, torso twists, ankle circles, dynamic
calf stretching, side stepping with wrist circles, split-step
knee bends, and quarter squats. The RT portion will occur
next and includes 5 exercises: leg press & leg flexion
(lower body), chest press, lat pull, and seated row (upper
body). These exercises are performed alternating between
lower and upper body exercises, with the number of repe-
titions, sets, and rest being modified every 4 weeks to in-
crease muscular strength. RT will progress from loads and
volumes appropriate for endurance (first 8 weeks) to those
appropriate for maximal strength gains (last 12 weeks).
Training volume, intensity, and rest are standardized and
described in Additional file 1: Table S1. Participants
should reach exhaustion at the last prescribed repetition
of the last set. Training prescription for all exercises
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follows American College of Sport Medicine guidelines
for strength development in older adults.
Following the RT portion of each session, partici-
pants will complete 2 sets of 10 min of aerobic exer-
cise. The mode of exercise can vary and may include
walking, a variety of ergometers (treadmill, elliptical
machines, cycling ergometers, rowing machines, etc.),
and other forms of free aerobic exercises, as long as
the cognitive load is minimized. Intensity will be mon-
itored using a Borg scale (0–10) with a target of 5–6
for weeks 1–8, 6–7 for weeks 9–16, and 7–8 for the
last 4 weeks (Additional file 2: Table S2).
Each session will end with a ten-minute cool down,
which will consist of the following stretches (each held
for 20–30 s); quadriceps stretch, hamstring stretch, calf
stretch, 2 hip stretches, static torso rotation, seated side
bend, back and shoulder stretch, chest stretch, triceps
stretch, neck stretch.
BAT control exercises
Participants assigned to the BAT control exercise con-
dition will take part in balance and toning exercises
in groups of up to eight participants, supervised by a
trainer [43–48]. The exercises will be devoted to im-
proving muscle tone and flexibility, without improving
strength, and cardiorespiratory capacity. Resistant load
and number of repetitions will not progress across
exercise sessions, unless participants were unable to
complete required repetitions at the beginning of the
intervention. The session will start with the same
10-min warm-up completed in the combined AE and
RT group. This will be followed by 40 min of a
variety of balance and toning exercises that will target
the entire body. The sessions will include functional
training (wall squats, standing calf raises, standing leg
abduction/adduction, standing ball walk up & down,
seated back row with resistance tube, shoulder retrac-
tions, wall push-ups, toe walking, heel walking, quar-
ter squats, gluteus kickback holds, standing ball
twists, shoulder circuits, yoga ball chest press, yoga
ball shoulder abduction, yoga ball leg adduction
squeeze), balance training (standing leg circumduc-
tion, tandem stance, single leg stance, tandem stance
ball relay pass, partner ball pass in tandem stance,
tandem forward & backward walking, toe taps on
bench), agility training (4 step zig zag in place, 4 step
zig zag walking, line and cone drills), and core train-
ing (core contractions seated on exercise ball, exercise
ball seated ball pass, seated exercise ball marching,
modified & full bug on floor). Exercises will be cycled
in and out every 3 weeks to maintain variety and
decrease likelihood of progression. The session will
end with the same 10 min cool down stretches as for
the exercise group.
Cognitive training
The cognitive training intervention will involve tablet
based (iPad®, held on a stand on a table) dual-task training
that requires participants to maintain and prepare for
many response alternatives (working memory) and to
share attention between two concurrent tasks (divided at-
tention). Difficulty of cognitive training is tailored to their
individual functioning level. The training uses a custom-
written program developed for neuro-rehabilitation and
has been used in previous research trials for cognitive [39,
40] and mobility outcomes [12].
Cognitive training will take place in groups of up to
eight participants before the exercise training session.
Cognitive training will be 30 min, at maximum, and each
participant will complete the cognitive training at an
individual desk space, in a quiet room, wearing head-
phones. Each session, participants will perform a two
different visuo-motor tasks, each with their respective
sets of visual stimuli (e.g., letters, numbers, animals,
vehicles, fruits, celestial bodies) and respective hand-
button correspondences (i.e., buttons that are to be
tapped with the thumbs on either the right or the left
side of the tablet). Participants are instructed to perform
as fast as possible, while maintaining accuracy. Tasks will
be performed both separately and concurrently so that
task-set cost and dual-task cost can be isolated. At each
session, task combination for the sets of stimuli will
change (from a total 18 combinations). Training will also
include online feedback as well as histogram of daily
performances to encourage improvement.
Control cognitive training
The cognitive training control group sessions will last a
maximum of 30 min to align with the same time frame
as the cognitive training group. Participants will alter-
nate between 2 different tasks (touristic searching using
internet and video watching) completed using the same
tablet (iPad®) as in the cognitive training group. Sessions
will be held in groups of up to eight participants, and in
the first session they will receive a short introductory
lesson on the use of the tablet and how to navigate the
internet. For the touristic searching using internet, par-
ticipants will be required to find 3 hotels, 3 touristic
places, and 3 restaurants of their own preference in a
city assigned by the instructor (a new city will be
selected each session). They will also need to include the
respective addresses of those places on their log sheet.
For the video watching task, participants will watch a
National Geographic video on YouTube selected by the
instructor with a different video selected each session.
They will watch the video for 20 min and during the
remaining 10 min they will answer the following ques-
tions on their log sheet; 1) what is the video about; 2)
what is the most important information in your opinion;
Montero-Odasso et al. BMC Geriatrics  (2018) 18:93 Page 9 of 15
3) create a question based on the video and answer your
own question. Despite completion of the tasks, partici-
pants will be stopped at 30 min.
Vitamin D supplementation
Participants will receive vitamin D supplementation (1
tablet of 10,000 IU of vitamin D3) three times per week
in order to reach a weekly cumulative dose of 30,000 IU
per week (equivalent of 4258 IU daily). The vitamin D
capsules will be provided by the research coordinator in
vials at the first session and every 4 weeks for a total of
five vials during the training period. Vials will be
returned by the participants to the research coordinator
at the end of each 4 week block. Rationale and bio-
safety of the dose: The dose of 10,000 IU/day is currently
approved by Health Canada as a supplementation for
older adults. Heaney et al. have administered doses of
30,000 IU/day vitamin D3 to adult men for 5 months,
with no significant changes in serum calcium concentra-
tions or adverse reactions [49–51]. A comprehensive
review of toxic effects of vitamin D found that the low-
est level at which an adverse effect was observed was a
serum calcidiol concentration of 200 nmol/l, corre-
sponding to a daily intake of 40,000 IU. Therefore,
weekly doses of 30,000 IU have a 9-fold weekly margin
of safety of the established safe dose.
Placebo vitamin D supplementation
Participants allocated to placebo vitamin D will receive a
placebo capsule that will perfectly match the vitamin D
tablets. They will take one tablet three times per week,
to match what the active vitamin D participants will be
taking. The vials will be dispensed on a 4 week basis in
the same manner as the vitamin D tablets.
Data analysis
Planned analysis
Descriptive statistics for demographic and baseline char-
acteristics will be provided with means and standard
deviations, or medians and the interquartile range where
appropriate, for continuous characteristics, and frequen-
cies and percentages for categorical variables. Analysis
will be conducted as intention-to-treat (ITT) and as
per-protocol analysis (PPA). Observation of a statistically
significant difference in the primary outcome at post-
intervention time point will be considered preliminary
evidence of efficacy. Contrasts from linear mixed models
containing the variable for intervention arm, the cat-
egorical variable for time points, and their interaction
term will be used for comparing continuous outcomes
such as ADAS-Cog scores, adjusting for baseline out-
come values and patient characteristics including age,
sex, and education. This approach can readily handle
three time points (baseline, 6 months and 12 months)
and thus may be regarded as a generalization of the
ANCOVA. Similar analyses for binary outcomes such as
reduction of prevalence rate of abnormal ADAS-Cog
plus score will be performed with generalized linear
mixed effect models. Specific contrasts from the mixed-
effects models will be constructed to test the following
hypotheses. The first hypothesis (exercise intervention)
will be evaluated by collapsing arms 1–4 (exercise inter-
vention, n = 160) and comparing them with arm 5 (no
exercise intervention, n = 40). For the second hypothesis
(cognitive intervention), arms 1–2 (cognitive interven-
tion, n = 80) and arms 3–4 (no cognitive intervention,
n = 80) will be collapsed and compared. For the third
hypothesis (vitamin D intervention), we will collapse
arms 1 and 3 (vitamin D intervention, n = 80) and com-
pare them with collapsed arms 2 and 4 (no vitamin D,
n = 80). For the fourth hypothesis (synergic effect), arm
1 (all active interventions, n = 40) will be compared
with arm 5 (all control interventions, n = 40).
For the secondary outcomes, 6 month changes in gait
performance and secondary cognitive outcomes of inter-
est will be performed using one way analyses of variance.
For group comparisons that are statistically significant,
pairwise comparisons will be made using Tukey’s mul-
tiple comparisons tests. Secondary analyses will be also
performed according to an intention-to-treat principle
and per-protocol analysis. An economic analysis will also
be performed.
All statistical tests will be two-tailed, and a p-value of
less than 0.05 will be considered to indicate statistical
significance. All calculations will be made using SPSS
(SPSS version 23.0, SPSS Inc., Chicago, IL) and Stata
(Stata Statistical Software: Release 14. College Station,
TX: StataCorp LP.).
Frequency of the analyses
Preliminary analysis will be performed after finishing
recruitment to ascertain descriptive characteristics at
baseline assessment. Interim efficacy analyses will be
performed when recruitment is reaching 50% of target
sample and final efficacy analysis will be performed at
the end of the trial since no safety issues are anticipated
in this study.
Adverse event and serious adverse event reporting
Adverse events will be recorded for subjects starting at
the time of signing the Informed Consent until their dis-
continuation of the study. All adverse events will be re-
corded on an ongoing paper log, which will be reviewed
by each site leader and forwarded to the team leader at
London site, who will determine both the intensity of
the event and the relationship of the event to study
procedures, and monitored until resolved. Based on the
outcome it will be up to the team leader to medically
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determine if it is justified for the participant to continue
in the study or terminate their participation. A serious
adverse event is defined as any incident that is unex-
pected, and related or possibly related to participation in
the research study.
Rescue medication and risk management
Higher doses of vitamin D may lead to hypervitaminosis
D manifested by hypercalcemia and its sequelae. Treat-
ment of acute or chronic intoxication includes withdrawal
of vitamin D3 and any calcium supplements, maintenance
of a low calcium diet and if needed corticosteroids or cal-
ciuric diuretics, such as furosemide and ethacrymic acid
to decrease serum calcium concentrations. All participants
will be monitored by site physicians and trained staff, and
should any adverse events arise, participants will have
access to a phone number and e-mail address provided on
the copy of their signed consent form. They will be
informed to use these contacts to notify the Principal
Investigator about concerns that may be associated with
treatment received in each site.
Ethical considerations
This study is conducted in compliance with International
Conference on Harmonization Good Clinical Practice
(ICH-GCP) and all applicable regulatory requirements.
Sponsor site obtained approval of the Research Ethics
Board at the University of Western Ontario (REB# 107670),
the Lawson Health Research Institute’s Clinical Research
Impact Committee (R-15-038), and Health Canada (HC file
- HC6–24-c195918 / HC protocol #201619) prior to initiat-
ing study-related activities. Each intervention site has also
obtained local ethical approval.
Discussion
Older adults with MCI are at a high risk of progression
to dementia syndromes with incident rates often ten
times higher than the cognitive healthy counterparts.
Additionally, older adults with MCI have an increased
risk of falling and mobility decline [52, 53]. Physical
exercise, cognitive training, and vitamin D supplementa-
tion are emerging and promising non-pharmacological
interventions to enhance mobility and cognitive func-
tioning in older adults, especially in pre-dementia states
such as MCI.
These three interventions have been tested separately,
with positive results for physical exercise and cognitive
training in improving cognitive function, and controver-
sial evidence for vitamin D supplementation [8, 19].
Importantly, it is currently unknown whether combining
AE with RT exercise has a better impact on cognitive
performance than a BAT exercise modality, and if an in-
tegrated approach including combined AE and RT exer-
cise in addition to cognitive training and vitamin D will
pose a synergistic efficacy for improving cognition and
mobility when compared with combined exercise alone.
Mechanistically, AE and RT exercises can provoke a cas-
cade of biochemical, physiological, and structural changes
in the brain, as summarised in Fig. 3. For example, AE
increases blood flow, neurotrophic factor release, neurogen-
esis, immune system efficacy and metabolism. These effects
of exercise could combat inflammatory processes and the
atrophy of brain structures both often associated with aging
and dementias [6, 22]. Interventions using RT exercises
have found substantial improvements in high-order cogni-
tion (e.g. executive functions), whereas low-order cognition
(e.g. attention, processing speed) is less benefited [6]. The
reason for this selective improvement in cognition is un-
known, but it is hypothesized that areas in the brain that
modulate executive functions are more susceptible to both
aging and physical exercises interventions. Mechanism sug-
gested involve modulation of insulin-like growth factor-1
and insulin sensitivity, decreasing inflammation, enhancing
release of brain-derived neurotrophic factor pathways, and
even decrease brain amyloid load [7, 54, 55]. Combined
exercise interventions have also shown increased brain
volume and muscle mass in older adults [44].
Cognitive training can also improve cognition through
enhancing brain functioning. Individuals who practiced
monitoring of two tasks at the same time (i.e. dual-task
training) on computer devices presented improved con-
nectivity between prefrontal and temporal cortices, areas
known to be important for executive functioning and
memory, when compared to control participants [13].
Furthermore, imaging in these participants showed in-
creased activity in these cortical areas during resting
state, as shown by increased blood flow. With this,
implementing a dual-task cognitive training program in
older adults has the potential to selectively improve
high-order cognitive functioning through brain plasticity
and improved activation.
Epidemiological evidence suggests that serum levels of
25-hydroxyvitamin D below 50 nmol is associated with
impaired executive functions and the development of
dementia [18]. Similarly, vitamin D levels in serum have
been associated with worse performance in the cognitive
motor interface in MCI populations. The reason of this
association remains to be determined; however, vitamin
D (25-hydroxyvitamin D) supplementation has been
hypothesized to cause enhancement of neuroprotective
agents that decrease biochemical processes in the brain
that accelerate cell death [19]. Activation of vitamin D
receptor inhibits the production of amyloid-β (Aβ) pro-
tein in the brain. Deregulated production of Aβ protein
influences a chain of biochemical mechanisms that in-
creases the rate of hippocampal cell death and synaptic
loss. Calcium function can also be regulated by vitamin
D via down regulation of L-type voltage-sensitive calcium
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channels decreasing apoptosis. Finally, vitamin D can
stabilize mitochondria leading to a reduction in oxidative
damage. Thus, we hypothesized that vitamin D could
modulate cognitive functioning through three major path-
ways: Aβ inhibition, calcium metabolism and mitochon-
drial activity [56]. Additionally, we have also hypothesized
that as a consequence of cognitive enhancement with
vitamin D supplementation, motor function may also be
improved [16, 57].
This randomized controlled trial is the first of its kind
to test whether a multimodal intervention combining
AE and RT with or without cognitive training or vitamin
D supplementation can improve cognition and mobility
related outcomes in older adults with MCI. Strengths of
our protocol include the selection of a comprehensive
battery of assessments sensitive to mobility-cognitive
changes, as determined in a previous Pan-Canadian
Consensus in Gait and Cognition (available at www.gai-
tandbrain.com/resources), and a population target, older
adults with MCI, which is thought to be the ideal stage
to intervene to delay cognitive decline before dementia.
Results for this study will provide data concerning the
effect size of the proposed multimodal interventions
compared with isolated interventions in cognitive and
mobility outcomes in MCI. We expect that the com-
bined exercise intervention will provide the larger effect
size contributing in the changes in cognitive outcomes
followed by the effects of cognitive training and vitamin
D supplementation.
In conclusion, the SYNERGIC Trail may contribute
to establish the efficacy of an integrated therapeutic
strategy, a multimodal approach, to stabilize and
reverse cognitive decline in older individuals with
MCI, and help to delay progression to dementia syn-
dromes. The proposed interventions are aimed at
improving the quality of life of many older adults
with significant cognitive decline and also alleviate
economic burdens on health care. It is estimated that
500,000 older Canadians have MCI [1] and even a
modest one-year delay in dementia incidence could
save the Canadian Health System over $109 billion
over 30 years [58].
Fig. 3 Conceptual model for individual and synergistic effects of planned interventions in the SYNERGIC Trial
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